Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Ten simple rules for a successful international consortium in big data omics

  • Stobbe, Miranda D.
  • González-Pérez, Abel
  • López Bigas, Núria
  • Gut, Ivo Glynne
We acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the co-funding with funds from the European Regional Development Fund corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014-2020 and MINECO/FEDER BIO2015-71792-P -awarded to IGG-. We thank the Departament de Salut and Departament de Recerca i Universitats of the Generalitat de Catalunya for its support through the CERCA programme and the co-funding with funds from the European Regional Development Fund corresponding to the Programa Operatiu FEDER de Catalunya 2014-2020. This project has received funding from the European Union's Horizon 2020 research and innovation programme through the EUCANCan project under grant agreement No 825835. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award (SEV-2015-0500) from the Spanish Ministry of Economy and Competitiveness and is supported by Centres de Recerca de Catalunya (Generalitat de Catalunya). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Examining microbe-metabolite correlations by linear methods

  • Quinn, Thomas P.
  • Erb, Ionas
Funding: I.E. has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 825835 (BovReg), Secretaria de Universidades e Investigación del Departamento de Economía y Conocimiento de la Generalidad de Cataluña, 2017 SGR 447 (SGR), Agencia Estatal de Investigación (AEI) and FEDER under Project BFU2017-88264-P (Plan Estatal). I.E. also acknowledges the following CRG funding sources: support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, Centro de Excelencia Severo Ochoa, the CERCA Programme / Generalitat de Catalunya and the European Regional Development Fund (ERDF)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Beltran, Sergi
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Palumbo, Emilio
  • Rambla de Argila, Jordi
  • Birney, Ewan
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cell-free DNA for genomic analysis in primary mediastinal large B-cell lymphoma

  • Rivas-Delgado, Alfredo
  • Nadeu, Ferran
  • Andrade-Campos, Marcio
  • López, Cristina
  • Enjuanes¸ Anna
  • Mozas, Pablo
  • Frigola, Gerard
  • Colomo Saperas, Luis Alberto
  • Sánchez González, Blanca
  • Villamor, Neus
  • Beà, Sílvia
  • Campo, Elias
  • Salar, Antonio
  • Giné, Eva
  • López Guillermo, Armando
  • Bellosillo Paricio, Beatriz
High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently occurs in primary mediastinal large B-cell lymphoma (PMBL). We used cfDNA for genomic characterization in 20 PMBL patients by means of a custom NGS panel for gene mutations and low-pass whole-genome sequencing (WGS) for copy number analysis (CNA) in a real-life setting. Appropriate cfDNA to perform the analyses was obtained in 18/20 cases. The sensitivity of cfDNA to detect the mutations present in paired FFPE samples was 69% (95% CI: 60-78%). The mutational landscape found in cfDNA samples was highly consistent with that of the tissue, with the most frequently mutated genes being B2M (61%), SOCS1 (61%), GNA13 (44%), STAT6 (44%), NFKBIA (39%), ITPKB (33%), and NFKBIE (33%). Overall, we observed a 75% concordance to detect CNA gains/losses between DNA microarray and low-pass WGS. The sensitivity of low-pass WGS was remarkably higher for clonal CNA (18/20, 90%) compared to subclonal alterations identified by DNA microarray. No significant associations between cfDNA amount and tumor burden or outcome were found. cfDNA is an excellent alternative source for the accurate genetic characterization of PMBL cases., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI16/00420 and PI19/00887 to A.L.-G. and E.G., PI17/00313 to L.C., PI19/0005 to B.B., and PI19/00034 to A.S., and co-funded by the European Union; CIBERONC [grant numbers CB16/12/00334, CB16/12/00225, and CB16/12/00241]; and the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health Research [grant number 825835 to E.C.]. F.N. acknowledges the research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, Grant Number 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, Grant Number RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021–2022, Grant Number LADY_TATA_21_3223). C.L. is supported by postdoctoral Beatriu de Pinós from Secretaria d’Universitats I Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya and by Marie Sklodowska-Curie COFUND program from H2020 (2018-BP-00055). E.C. is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” (ICREA) [no grant number applies] of the Generalitat de Catalunya. We also acknowledge the support of the CERCA Program from Generalitat de Catalunya [no grant number applies].
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Bridging the European Data Sharing Divide in Genomic Science

  • Molnár Gábor, Fruzsina
  • Beauvais, Michael J. S.
  • Bernier, Alexander
  • Nicolás Jiménez, María Pilar
  • Recuero Linares, Mikel
In this viewpoint, we argue for the importance of creating data spaces for genomic research that are detached from contexts in which fundamental rights concerns related to surveillance measures override a purpose-specific balancing of fundamental rights. Genomic research relies on molecular and phenotypic data, on comparing findings within large data sets, on searchable metadata, and on translating research results into a clinical setting. These methods require sensitive genetic and health data to be shared across borders. International data sharing between the European Union (EU) or the European Economic Area and third countries has accordingly become a cornerstone of genomics. The EU General Data Protection Regulation contains rules that accord privileged status to data processing for research purposes to ensure that strict data protection requirements do not impede biomedical research. However, the General Data Protection Regulation rules applicable to international transfers of data accord no such preferential treatment to international data transfers made in the research context. The rules that govern the international transfer of data create considerable barriers to international data sharing because of the cost-intensive procedural and substantive compliance burdens that they impose. For certain jurisdictions and select use cases, there exist practically no lawful mechanisms to enable the international transfer of data because of concerns about the protection of fundamental rights. The proposed solutions further fail to address the need to share large data sets of local and regional cohorts across national borders to enable joint analyses. The European Health Data Space is an emerging federated, EU-wide data infrastructure that is intended to function as an infrastructure bringing together EU health data to improve patient care and enable the secondary use of health-related data for research purposes. Such infrastructure is implementing new institutions to support its functioning and is being implemented in reliance on a new enabling law, the regulation on the European Health Data Space. This innovation provides the opportunity to facilitate EU contribution to international genomic research efforts. The draft regulation for this data space provides for a concept of data infrastructure intended to enable cross-border data exchange and access, including access to genetic and health data for scientific analysis purposes. The draft regulation also provides for obligations of national actors aimed at making data widely available. This effort is laudable. However, in the absence of further, more fundamental changes to the manner in which the EU regulates the secondary use of health data, it is reasonable to believe that EU participation in international genomic research efforts will remain impeded., This project has received funding from the European Union Horizon 2020 research and innovation program under grant agreement 825835 and the European-Canadian Cancer Network (EUCANCan), a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management, and sharing of genomic oncology data for personalized medicine. MB, AB, and BMK received funding support for this work from the Canada Foundation for Innovation Cyberinfrastructure Initiative; the Ontario Research Fund; the British Columbia Knowledge Development Fund; and the Ministère de l’Économie, de la Science et de l’Innovation for The Cancer Genome Collaboratory project, as well as from the Canada Research Chair in Law and Medicine. FMG is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation)—NFDI 1/1 “German Human Genome-Phenome Archive.” FMG, AB, PN, MRL, and BMK are members of the ethico-legal work package of the EUCANCan consortium. The authors are grateful for the collaborative spirit within EUCANCan and for the open exchange with all members of the consortium
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Page, Angela
  • Smith, Lindsay
  • Adams, Jeremy B.
  • Alterovitz, Gil
  • Babb, Lawrence J.
  • Barkley, Maxmillian P.
  • Baudis, Michael
  • Beauvais, Michael J. S.
  • Beck, Tim
  • Beckmann, Jacques S.
  • Varma, Susheel
  • Vears, Danya F.
  • Viner, Coby
  • Voisin, Craig
  • Wagner, Alex H.
  • Wallace, Susan E.
  • Walsh, Brian P.
  • Williams, Marc S.
  • Winkler, Eva C.
  • Brudno, Michael
  • Kelleher, Jerome
  • Wold, Barbara J.
  • Wood, Grant M.
  • Woolley, J. Patrick
  • Yamasaki, Chisato
  • Yates, Andrew D.
  • Yung, Christina K.
  • Zass, Lyndon J.
  • Zaytseva, Ksenia
  • Zhang, Junjun
  • Goodhand, Peter
  • Kerry, Giselle
  • Brush,Matthew H.
  • North, Kathryn
  • Birney, Ewan
  • Bujold, David
  • Burdett, Tony
  • Buske, Orion J.
  • Cabili, Moran N.
  • Cameron, Daniel L.
  • Carroll, Robert J.
  • Casas-Silva, Esmeralda
  • Khor, Seik-Soon
  • Chakravarty, Debyani
  • Chaudhari, Bimal P.
  • Chen, Shu Hui
  • Cherry, J. Michael
  • Chung, Justina
  • Cline, Melissa
  • Clissold, Hayley L.
  • Cook-Deegan, Robert M.
  • Courtot, Melanie
  • Cunningham, Fiona
  • Knoppers, Bartha M.
  • Cupak, Miro
  • Davies, Robert M.
  • Denisko, Danielle
  • Doerr, Megan J.
  • Dolman, Lena I.
  • Dove, Edward S.
  • Dursi, Lewis Jonathan
  • Dyke, Stephanie O. M.
  • Eddy, James A.
  • Eilbeck, Karen
  • Konopko, Melissa A.
  • Ellrott, Kyle P.
  • Fairley, Susan
  • Fakhro, Khalid A.
  • Firth, Helen V.
  • Fitzsimons, Michael S.
  • Fiume, Marc
  • Flicek, Paul
  • Fore, Ian M.
  • Freeberg, Mallory A.
  • Freimuth, Robert R.
  • Kosaki, Kenjiro
  • Fromont, Lauren A.
  • Fuerth, Jonathan
  • Gaff, Clara L.
  • Gan, Weiniu
  • Ghanaim, Elena M.
  • Glazer, David
  • Green, Robert C.
  • Griffith, Malachi
  • Griffith, Obi L.
  • Grossman, Robert L.
  • Kuba, Martin
  • Groza, Tudor
  • Guidry Auvil, Jaime M.
  • Guigó, Roderic
  • Gupta, Dipayan
  • Haendel, Melissa A.
  • Hamosh, Ada
  • Hansen, David P.
  • Hart, Reece K.
  • Hartley, Dean Mitchell
  • Haussler, David
  • Lawson, Jonathan
  • Hendricks-Sturrup, Rachele M.
  • Ho, Calvin W. L.
  • Hobb, Ashley E.
  • Hoffman, Michael M.
  • Hofmann, Oliver M.
  • Holub, Petr
  • Shujui Hsu, Jacob
  • Hubaux, Jean-Pierre
  • Hunt, Sarah E.
  • Husami, Ammar
  • Leinonen, Rasko
  • Jacobsen, Julius O.
  • Jamuar, Saumya S.
  • Janes, Elizabeth L.
  • Jeanson, Francis
  • Jene, Aina
  • Johns, Amber L.
  • Joly, Yann
  • Jones, Steven J. M.
  • Kanitz, Alexander
  • Kato, Kazuto
  • Li, Stephanie
  • Keane, Thomas M.
  • Kekesi-Lafrance, Kristina
  • Beltran, Sergi
  • Lin, Michael F.
  • Linden, Mikael
  • Liu, Xianglin
  • Udara Liyanage, Isuru
  • López, Javier
  • Lucassen, Anneke M.
  • Lukowski, Michael
  • Mann, Alice L.
  • Marshall, John
  • Mattioni, Michele
  • Bernick, David
  • Metke-Jiménez, Alejandro
  • Middleton, Anna
  • Milne, Richard J.
  • Molnár-Gábor, Fruzsina
  • Mulder, Nicola
  • Muñoz-Torres, Mónica C.
  • Nag, Rishi
  • Nakagawa, Hidewaki
  • Nasir, Jamal
  • Navarro, Arcadi
  • Bernier, Alexander
  • Nelson, Tristan H.
  • Niewielska, Ania
  • Nisselle, Amy
  • Niu, Jeffrey
  • Nyrönen, Tommi H.
  • O’Connor, Brian D.
  • Oesterle, Sabine
  • Ogishima, Soichi
  • Wang, Vivian Ota
  • Paglione, Laura A. D.
  • Bonfield, James K.
  • Palumbo, Emilio
  • Parkinson, Helen E.
  • Philippakis, Anthony A.
  • Pizarro, Angel D.
  • Prlic, Andreas
  • Rambla, Jordi
  • Rendon, Augusto
  • Rider, Renee A.
  • Robinson, Peter N.
  • Rodarmer, Kurt W.
  • Boughtwood, Tiffany F.
  • Lyman Rodríguez, Laura
  • Rubin, Alan F.
  • Rueda, Manuel
  • Rushton, Gregory A.
  • Ryan, Rosalyn S.
  • Saunders, Gary I.
  • Schuilenburg, Helen
  • Schwede, Torsten
  • Scollen, Serena
  • Senf, Alexander
  • Bourque, Guillaume
  • Sheffield, Nathan C.
  • Skantharajah, Neerjah
  • Smith, Albert V.
  • Sofia, Heidi J.
  • Spalding, Dylan
  • Spurdle, Amanda B.
  • Stark, Zornitza
  • Stein, Lincoln D.
  • Suematsu, Makoto
  • Tan, Patrick
  • Bowers, Sarion R.
  • Tedds, Jonathan A.
  • Thomson, Alastair A.
  • Thorogood, Adrian
  • Tickle, Timothy L.
  • Tokunaga, Katsushi
  • Törnroos,Juha
  • Torrents, David
  • Upchurch, Sean
  • Valencia, Alfonso
  • Valls Guimera, Roman
  • Brookes, Anthony J.
  • Vamathevan, Jessica
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

ONCOLINER: A new solution for monitoring, improving, and harmonizing somatic variant calling across genomic oncology centers

  • Martin, Rodrigo
  • Gaitán, Nicolas
  • Jarlier, Frédéric
  • Feuerbach, Lars
  • Soyres, Henri de
  • Arbones, Marc
  • Puiggròs, Montserrat
  • Ferriz, Alvaro
  • Gonzalez, Asier
  • Capella Gutiérrez, Salvador|||0000-0002-0309-604X
  • Royo, Romina|||0000-0003-3493-0874
  • Torrents, David
The characterization of somatic genomic variation associated with the biology of tumors is fundamental for cancer research and personalized medicine, as it guides the reliability and impact of cancer studies and genomic-based decisions in clinical oncology. However, the quality and scope of tumor genome analysis across cancer research centers and hospitals are currently highly heterogeneous, limiting the consistency of tumor diagnoses across hospitals and the possibilities of data sharing and data integration across studies. With the aim of providing users with actionable and personalized recommendations for the overall enhancement and harmonization of somatic variant identification across research and clinical environments, we have developed ONCOLINER. Using specifically designed mosaic and tumorized genomes for the analysis of recall and precision across somatic SNVs, insertions or deletions (indels), and structural variants (SVs), we demonstrate that ONCOLINER is capable of improving and harmonizing genome analysis across three state-of-the-art variant discovery pipelines in genomic oncology., BSC-CNS discloses support for the research of this work from the European Union’s Horizon 2020 research and innovation programme under EUCANCan (grant agreement no. 825835), the Instituto de Salud Carlos III (ISCIII) and “Unión Europea NextGenerationEU/Mecanismo para la Recuperación y la Resilencia (MRR)/PRTR” under project PMP21/00015, the Departament de Recerca i Universitats de la Generalitat de Catalunya (code: 2021 SGR 01626), and the Science and Innovation Spanish Ministry under project BenchSV (PID2020-119797RB-I00/AEI/10.13039/501100011033). Institut Curie discloses support for the research of this work from the European Union’s Horizon 2020 research and innovation programme under EUCANCan (grant agreement no. 825835) and Cancéropôle Île-de-France (grant GENOPROFILE - RIC2021). The German Cancer Research Center (DKFZ) received funding from the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health Research under the grant agreement no. 825325. CNAG institutional support was from the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias, and cofunded with ERDF funds (PI19/01772); the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III; the 2014–2020 Smart Growth Operating Program and institutional co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P); and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement. We acknowledge Hartwig Medical Foundation for their help and contributions to different parts of the study. We specifically thank and highly appreciate the valuable contribution of Matias Mendeville. In addition, we would like to express our sincere gratitude to the Genome in a Bottle Consortium (GIAB), the International Cancer Genome Consortium (ICGC), and The Cancer Genome Atlas (TCGA) for making high-quality data accessible through secure protocols, which have been instrumental to the success of this study., Peer Reviewed, "Article signat per 18 autors/es: Rodrigo Martín ∙ Nicolás Gaitán ∙ Frédéric Jarlier ∙ Lars Feuerbach ∙ Henri de Soyres ∙ Marc Arbonés ∙ Tom Gutman ∙ Montserrat Puiggròs ∙ Alvaro Ferriz ∙ Asier Gonzalez ∙ Lucía Estelles ∙ Ivo Gut ∙ Salvador Capella-Gutierrez ∙ Lincoln D. Stein ∙ Benedikt Brors ∙ Romina Royo ∙ Philippe Hupé ∙ David Torrents"
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ten simple rules for a successful international consortium in big data omics

  • Stobbe, Miranda D.
  • González-Pérez, Abel
  • López Bigas, Núria
  • Gut, Ivo Glynne
We acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the co-funding with funds from the European Regional Development Fund corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014-2020 and MINECO/FEDER BIO2015-71792-P -awarded to IGG-. We thank the Departament de Salut and Departament de Recerca i Universitats of the Generalitat de Catalunya for its support through the CERCA programme and the co-funding with funds from the European Regional Development Fund corresponding to the Programa Operatiu FEDER de Catalunya 2014-2020. This project has received funding from the European Union's Horizon 2020 research and innovation programme through the EUCANCan project under grant agreement No 825835. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award (SEV-2015-0500) from the Spanish Ministry of Economy and Competitiveness and is supported by Centres de Recerca de Catalunya (Generalitat de Catalunya). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cell-free DNA for genomic analysis in primary mediastinal large B-cell lymphoma

  • Rivas-Delgado, Alfredo
  • Nadeu, Ferran
  • Andrade-Campos, Marcio
  • López, Cristina
  • Enjuanes¸ Anna
  • Mozas, Pablo
  • Frigola, Gerard
  • Colomo Saperas, Luis Alberto
  • Sánchez González, Blanca
  • Villamor, Neus
  • Beà, Sílvia
  • Campo, Elias
  • Salar, Antonio
  • Giné, Eva
  • López Guillermo, Armando
  • Bellosillo Paricio, Beatriz
High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently occurs in primary mediastinal large B-cell lymphoma (PMBL). We used cfDNA for genomic characterization in 20 PMBL patients by means of a custom NGS panel for gene mutations and low-pass whole-genome sequencing (WGS) for copy number analysis (CNA) in a real-life setting. Appropriate cfDNA to perform the analyses was obtained in 18/20 cases. The sensitivity of cfDNA to detect the mutations present in paired FFPE samples was 69% (95% CI: 60-78%). The mutational landscape found in cfDNA samples was highly consistent with that of the tissue, with the most frequently mutated genes being B2M (61%), SOCS1 (61%), GNA13 (44%), STAT6 (44%), NFKBIA (39%), ITPKB (33%), and NFKBIE (33%). Overall, we observed a 75% concordance to detect CNA gains/losses between DNA microarray and low-pass WGS. The sensitivity of low-pass WGS was remarkably higher for clonal CNA (18/20, 90%) compared to subclonal alterations identified by DNA microarray. No significant associations between cfDNA amount and tumor burden or outcome were found. cfDNA is an excellent alternative source for the accurate genetic characterization of PMBL cases., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI16/00420 and PI19/00887 to A.L.-G. and E.G., PI17/00313 to L.C., PI19/0005 to B.B., and PI19/00034 to A.S., and co-funded by the European Union; CIBERONC [grant numbers CB16/12/00334, CB16/12/00225, and CB16/12/00241]; and the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health Research [grant number 825835 to E.C.]. F.N. acknowledges the research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, Grant Number 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, Grant Number RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021–2022, Grant Number LADY_TATA_21_3223). C.L. is supported by postdoctoral Beatriu de Pinós from Secretaria d’Universitats I Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya and by Marie Sklodowska-Curie COFUND program from H2020 (2018-BP-00055). E.C. is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” (ICREA) [no grant number applies] of the Generalitat de Catalunya. We also acknowledge the support of the CERCA Program from Generalitat de Catalunya [no grant number applies].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Beltran, Sergi
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Palumbo, Emilio
  • Rambla de Argila, Jordi
  • Birney, Ewan
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Examining microbe-metabolite correlations by linear methods

  • Quinn, Thomas P.
  • Erb, Ionas
Funding: I.E. has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 825835 (BovReg), Secretaria de Universidades e Investigación del Departamento de Economía y Conocimiento de la Generalidad de Cataluña, 2017 SGR 447 (SGR), Agencia Estatal de Investigación (AEI) and FEDER under Project BFU2017-88264-P (Plan Estatal). I.E. also acknowledges the following CRG funding sources: support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, Centro de Excelencia Severo Ochoa, the CERCA Programme / Generalitat de Catalunya and the European Regional Development Fund (ERDF)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ONCOLINER: A new solution for monitoring, improving, and harmonizing somatic variant calling across genomic oncology centers

  • Martin, Rodrigo
  • Gaitán, Nicolas
  • Jarlier, Frédéric
  • Feuerbach, Lars
  • Soyres, Henri de
  • Arbones, Marc
  • Puiggròs, Montserrat
  • Ferriz, Alvaro
  • Gonzalez, Asier
  • Capella Gutiérrez, Salvador
  • Royo, Romina
  • Torrents, David
The characterization of somatic genomic variation associated with the biology of tumors is fundamental for cancer research and personalized medicine, as it guides the reliability and impact of cancer studies and genomic-based decisions in clinical oncology. However, the quality and scope of tumor genome analysis across cancer research centers and hospitals are currently highly heterogeneous, limiting the consistency of tumor diagnoses across hospitals and the possibilities of data sharing and data integration across studies. With the aim of providing users with actionable and personalized recommendations for the overall enhancement and harmonization of somatic variant identification across research and clinical environments, we have developed ONCOLINER. Using specifically designed mosaic and tumorized genomes for the analysis of recall and precision across somatic SNVs, insertions or deletions (indels), and structural variants (SVs), we demonstrate that ONCOLINER is capable of improving and harmonizing genome analysis across three state-of-the-art variant discovery pipelines in genomic oncology., BSC-CNS discloses support for the research of this work from the European Union’s Horizon 2020 research and innovation programme under EUCANCan (grant agreement no. 825835), the Instituto de Salud Carlos III (ISCIII) and “Unión Europea NextGenerationEU/Mecanismo para la Recuperación y la Resilencia (MRR)/PRTR” under project PMP21/00015, the Departament de Recerca i Universitats de la Generalitat de Catalunya (code: 2021 SGR 01626), and the Science and Innovation Spanish Ministry under project BenchSV (PID2020-119797RB-I00/AEI/10.13039/501100011033). Institut Curie discloses support for the research of this work from the European Union’s Horizon 2020 research and innovation programme under EUCANCan (grant agreement no. 825835) and Cancéropôle Île-de-France (grant GENOPROFILE - RIC2021). The German Cancer Research Center (DKFZ) received funding from the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health Research under the grant agreement no. 825325. CNAG institutional support was from the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias, and cofunded with ERDF funds (PI19/01772); the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III; the 2014–2020 Smart Growth Operating Program and institutional co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P); and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement. We acknowledge Hartwig Medical Foundation for their help and contributions to different parts of the study. We specifically thank and highly appreciate the valuable contribution of Matias Mendeville. In addition, we would like to express our sincere gratitude to the Genome in a Bottle Consortium (GIAB), the International Cancer Genome Consortium (ICGC), and The Cancer Genome Atlas (TCGA) for making high-quality data accessible through secure protocols, which have been instrumental to the success of this study., Peer Reviewed, "Article signat per 18 autors/es: Rodrigo Martín ∙ Nicolás Gaitán ∙ Frédéric Jarlier ∙ Lars Feuerbach ∙ Henri de Soyres ∙ Marc Arbonés ∙ Tom Gutman ∙ Montserrat Puiggròs ∙ Alvaro Ferriz ∙ Asier Gonzalez ∙ Lucía Estelles ∙ Ivo Gut ∙ Salvador Capella-Gutierrez ∙ Lincoln D. Stein ∙ Benedikt Brors ∙ Romina Royo ∙ Philippe Hupé ∙ David Torrents", Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].